Latest Earnings Results: Q3 '26
Estimated EPS
-$0.30
Reported EPS
-$0.07
Surprise
+76.67%
Estimated Rev
$5.47M
Reported Rev
$6.41M
Surprise
+17.15%
Vivos expects clinical initiatives and payer contract renegotiations to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.20 | -- | -- | N/A |
Q3 '26 | -$0.30 | -$0.07 | 76.67% | BEAT |
Q2 '26 | -$0.41 | -$0.31 | 24.39% | BEAT |
Q1 '26 | -$0.45 | -$0.52 | -14.71% | MISSED |
Q4 '25 | -$0.50 | -$0.58 | -17.17% | MISSED |